GlassScriptPhysician profile
Anila Abraham
NPI 1790237543
$6,865.13
in general payments reported to CMS, 2019-2025
55 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $1,023 · 2023: $2,315 · 2024: $2,877 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,861 · Education: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,861.45 |
| Education | $516.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $805.53 | 2021-2025 | Lynparza, Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $524.44 | 2022-2024 | |
| Janssen Biotech, INC. | $313.88 | 2022-2025 | Darzalex, Tecvayli, Imbruvica |
| Incyte Corporation | $313.65 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Ipsen Biopharmaceuticals, INC | $295.14 | 2022-2024 | Tazverik, Onivyde, Somatuline Depot |
| Exelixis INC. | $293.35 | 2023-2025 | Cabometyx |
| Pfizer INC. | $290.35 | 2023-2024 | |
| Glaxosmithkline, LLC. | $275.84 | 2023-2025 | Ojjaara, Blenrep |
| Astellas Pharma US INC | $267.39 | 2022-2025 | Xtandi, Xospata, Padcev |
| Sobi, INC | $250.38 | 2022-2024 | |
| Abbvie INC. | $231.92 | 2022-2025 | |
| Genentech USA, INC. | $201.52 | 2022-2024 | Venclexta, Polivy, Lunsumio |
| Eisai INC. | $185.10 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $177.24 | 2022-2024 | Opdualag, Opdivo |
| Sanofi-Aventis U.S. LLC | $169.98 | 2023 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $165.93 | 2021-2024 | |
| Genzyme Corporation | $159.12 | 2022-2024 | |
| Seagen INC. | $150.65 | 2021-2023 | Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $150.41 | 2022-2024 | Alunbrig, Vpriv, Iclusig |
| Rigel Pharmaceuticals, INC. | $131.49 | 2021-2024 | Tavalisse, Rezlidhia |
| Pharmacyclics LLC, An Abbvie Company | $109.08 | 2022-2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $108.32 | 2023-2024 | |
| Ethicon US, LLC | $99.73 | 2021 | |
| Emd Serono, INC. | $93.77 | 2023-2024 | Bavencio |
| Lilly USA, LLC | $83.67 | 2024 | Verzenio, Jaypirca, Retevmo |
| Karyopharm Therapeutics INC. | $75.33 | 2022-2024 | Xpovio |
| Alexion Pharmaceuticals, INC. | $64.39 | 2024 | Ultomiris |
| Daiichi Sankyo INC. | $59.58 | 2022-2023 | Enhertu |
| Adaptive Biotechnologies Corporation | $59.57 | 2022-2024 | Clonoseq |
| Mirati Therapeutics, INC. | $58.33 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $58.07 | 2023-2024 | |
| Beigene USA, INC. | $51.28 | 2023-2024 | Brukinsa |
| Acrotech Biopharma INC. | $48.87 | 2023-2024 | Beleodaq |
| Array Biopharma INC | $45.93 | 2023-2024 | Mektovi, Braftovi, Lorbrena |
| Merck Sharp & Dohme LLC | $45.60 | 2022-2023 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $42.71 | 2023-2024 | Libtayo |
| Celgene Corporation | $39.90 | 2022-2023 | Opdualag |
| Taiho Oncology, INC. | $36.07 | 2022 | |
| Amgen INC. | $34.06 | 2023 | Lumakras |
| Kite Pharma, INC. | $25.32 | 2022 | |
| Stemline Therapeutics INC. | $22.57 | 2024 | Orserdu |
| Cti Biopharma Corp. | $22.19 | 2023 | Vonjo |
| G1 Therapeutics, INC. | $19.36 | 2022 | |
| Azurity Pharmaceuticals, INC. | $19.32 | 2024 | Vivimusta |
| Coherus Oncology, INC. | $19.30 | 2023 | |
| Gilead Sciences, INC. | $19.02 | 2024 | |
| Kyowa Kirin, INC. | $18.90 | 2023 | Poteligeo |
| Morphosys, US INC. | $18.61 | 2023 | Monjuvi |
| Legend Biotech USA INC. | $18.44 | 2024 | |
| Adc Therapeutics America, INC. | $18.32 | 2024 | |
| Sumitomo Pharma America, INC. | $17.47 | 2023 | Orgovyx |
| Janssen Pharmaceuticals, INC | $16.43 | 2023 | Xarelto |
| Genmab U.S., INC. | $15.00 | 2023 | Epkinly |
| Pharmacosmos Therapeutics INC. | $14.24 | 2023 | Monoferric |
| Myovant Sciences INC. | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anila Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.